| OAB0702 | Overlapping significant life events are associated with HIV viral non-suppression among youth in clinics in rural East Africa | Oral abstract session with live Q&A | B51 |
| OAB0703 | Improving pediatric index testing: Data from 12 PEPFAR-supported countries in sub-Saharan Africa | Oral abstract session with live Q&A | B47 |
| OAB0704 | Biomarker assessment of infant adherence to isoniazid prophylaxis in a primary TB infection prevention trial in Kenya | Oral abstract session with live Q&A | B55 |
| OAB0705 | Rates of cervical lesions by age and previous screening status and enhancing treatment among women living with HIV (WLHIV) in sub-Saharan Africa within the Go Further partnership | Oral abstract session with live Q&A | B14 |
| OAB0706 | Plasma exposure-viral load response analysis for dolutegravir in children with HIV-1: Results from IMPAACT P1093 | Oral abstract session with live Q&A | B48 |
| OABLB0101 | Safety, pharmacokinetics and efficacy of low-dose E/C/F/TAF in virologically suppressed children '¥2 years old living with HIV | Oral abstract session with live Q&A | B50 |
| OABLB0102 | Clinical outcomes by HIV serostatus, CD4 count, and viral suppression among people hospitalized with COVID-19 in the Bronx, New York | Oral abstract session with live Q&A | B69 |
| OABLB0103 | The predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trial | Oral abstract session with live Q&A | B44 |
| OABLB0104 | Immunologic characteristics of acute COVID-19 in people with HIV | Oral abstract session with live Q&A | B69 |
| OABLB0105 | Faster virological suppression with dolutegravir versus efavirenz in pregnancy does not lower the risk of HIV mother-to-child-transmission: A meta-analysis of 5 clinical trials in 1074 pregnant women | Oral abstract session with live Q&A | B44 |